BLMS (Bloomios) Debt-to-Asset : 12.72 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bloomios Debt-to-Asset?

Bloomios BLMS Debt-to-Asset is 12.72 as of Sep. 2023.

Bloomios's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $24.31 Mil. Bloomios's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.27 Mil. Bloomios's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $1.93 Mil. Bloomios's debt to asset for the quarter that ended in Sep. 2023 was 12.72.


Bloomios  (OTCPK:BLMS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Bloomios Debt-to-Asset Related Terms


Bloomios Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Bloomios's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bloomios Debt-to-Asset Chart

Bloomios Annual Data
Trend Jun02 Jun03 Jun04 Jan05 Jan06 Jan07 Jan19 Jan20 Dec21 Dec22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.70 0.00 0.00 0.64 0.86

Bloomios Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.70 0.86 0.89 0.92 12.72

BLMS vs MJNE, ACORQ, ZTS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bloomios Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bloomios's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bloomios's Debt-to-Asset falls into.



Bloomios Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bloomios's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Bloomios's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(24.313 + 0.269) / 1.932
=12.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 12.72 mean?
Bloomios (BLMS) has a Debt-to-Asset of 12.72 as of Sep. 2023. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Bloomios and its competitors.
Is Bloomios' Debt-to-Asset too high?
Bloomios' current Debt-to-Asset is 12.72.
How does Bloomios' Debt-to-Asset compare to MJNE and ACORQ?
Bloomios' Debt-to-Asset of 12.72 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Bloomios and its competitors. Bloomios's current Debt-to-Asset is 12.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bloomios stock overvalued right now?
Bloomios (BLMS) has a current Debt-to-Asset of 12.72. The current Debt-to-Asset is 12.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Bloomios (BLMS), the current Debt-to-Asset is 12.72 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bloomios Business Description

Address 701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101
Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.